Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study.
Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study.
复制标题
DOI：
10.1186/s12916-022-02333-0
复制
发表时间：
2022-04-04
期刊：
影响因子：
9.3
通讯作者：
Yu H
中科院分区：
文献类型：
--
作者：
Chen Z;Zheng W;Wu Q;Chen X;Peng C;Tian Y;Sun R;Dong J;Wang M;Zhou X;Zhao Z;Zhong G;Yan X;Liu N;Hao F;Zhao S;Zhuang T;Yang J;Azman AS;Yu H
全球已接种数亿剂2019冠状病毒病（COVID-19）疫苗，但各国的疫苗接种进展差异很大。我们旨在提供COVID-19疫苗接种活动的整体情况，包括COVID-19疫苗的政策、覆盖范围和需求。我们对截至2022年2月8日从多个公共来源获得的疫苗接种政策和接种剂量数据进行了描述性研究。我们使用这些数据来制定覆盖率指标，并探索疫苗覆盖率与社会经济和医疗保健相关因素的关系。我们根据各国的国家免疫规划政策，将疫苗需求量估计为完成目标人群疫苗接种所需的剂量。信使RNA和腺病毒载体疫苗是高收入国家最常用的COVID-19疫苗，而腺病毒载体疫苗是全球最广泛使用的疫苗（180个国家）。192个国家已授权公众接种疫苗，其中40.1%（77/192）的疫苗针对12岁以上的人群，32.3%（62/192）的疫苗针对≥ 5岁的人群。分别有48个和151个国家启动了额外剂量和加强剂量疫苗接种计划。在全球范围内，目标人群中每100人接种了162.1剂，区域间和国家间存在明显的异质性。完成的疫苗接种系列覆盖率范围为国家目标人群的0.1%至95.0%以上，目标人群中每100人接种的剂量数范围为0.2至308.6剂。整个人群中每100人的给药剂量与医疗保健可及性和质量指数（R2 = 0.59）、社会人口统计学指数（R2 = 0.52）和人均国内生产总值（R2 = 0.61）相关。完成临时疫苗接种计划至少需要64亿剂疫苗，其中33亿剂用于初级免疫，31亿剂用于额外/加强免疫计划。在全球范围内，初级免疫和额外/加强剂量方案分别需要目标人群中每人0.53和0.74剂。在COVID-19疫苗的推广方面存在着广泛的国家层面差异和不公平，这表明免疫力存在巨大差距，特别是在低收入国家。在线版本包含补充材料，可通过10.1186/s12916-022-02333-0获得。
Hundreds of millions of doses of coronavirus disease 2019 (COVID-19) vaccines have been administered globally, but progress on vaccination varies considerably between countries. We aimed to provide an overall picture of COVID-19 vaccination campaigns, including policy, coverage, and demand of COVID-19 vaccines. We conducted a descriptive study of vaccination policy and doses administered data obtained from multiple public sources as of 8 February 2022. We used these data to develop coverage indicators and explore associations of vaccine coverage with socioeconomic and healthcare-related factors. We estimated vaccine demand as numbers of doses required to complete vaccination of countries’ target populations according to their national immunization program policies. Messenger RNA and adenovirus vectored vaccines were the most commonly used COVID-19 vaccines in high-income countries, while adenovirus vectored vaccines were the most widely used vaccines worldwide (180 countries). One hundred ninety-two countries have authorized vaccines for the general public, with 40.1% (77/192) targeting individuals over 12 years and 32.3% (62/192) targeting those ≥ 5 years. Forty-eight and 151 countries have started additional-dose and booster-dose vaccination programs, respectively. Globally, there have been 162.1 doses administered per 100 individuals in target populations, with marked inter-region and inter-country heterogeneity. Completed vaccination series coverage ranged from 0.1% to more than 95.0% of country target populations, and numbers of doses administered per 100 individuals in target populations ranged from 0.2 to 308.6. Doses administered per 100 individuals in whole populations correlated with healthcare access and quality index (R2 = 0.59), socio-demographic index (R2 = 0.52), and gross domestic product per capita (R2 = 0.61). At least 6.4 billion doses will be required to complete interim vaccination programs—3.3 billion for primary immunization and 3.1 billion for additional/booster programs. Globally, 0.53 and 0.74 doses per individual in target populations are needed for primary immunization and additional/booster dose programs, respectively. There is wide country-level disparity and inequity in COVID-19 vaccines rollout, suggesting large gaps in immunity, especially in low-income countries. The online version contains supplementary material available at 10.1186/s12916-022-02333-0.
登录
查看更多内容
影响因子：
56.9
作者：
Campos-Mercade, Pol;Meier, Armando N.;Schneider, Florian H.;Meier, Stephan;Pope, Devin;Wengstrom, Erik
通讯作者：
Wengstrom, Erik
影响因子：
5.5
作者：
Teresa Aguado M;Barratt J;Beard JR;Blomberg BB;Chen WH;Hickling J;Hyde TB;Jit M;Jones R;Poland GA;Friede M;Ortiz JR
通讯作者：
Ortiz JR
DOI：
10.15585/mmwr.mm7022e1
发表时间：
2021-06-04
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Barry V;Dasgupta S;Weller DL;Kriss JL;Cadwell BL;Rose C;Pingali C;Musial T;Sharpe JD;Flores SA;Greenlund KJ;Patel A;Stewart A;Qualters JR;Harris L;Barbour KE;Black CL
通讯作者：
Black CL
影响因子：
5.5
作者：
Burke PF;Masters D;Massey G
通讯作者：
Massey G
影响因子：
3.7
作者：
Kumar S;Quinn SC;Kim KH;Hilyard KM
通讯作者：
Hilyard KM